Focused-ultrasound developer InSightec has received U.S. Food and Drug Administration (FDA) clearance for a new software version for its ExAblate 2000 MR-guided focused ultrasound (MRgFUS) system.
The new software employs an "interleaved" treatment mode that allows the system to target different parts of the fibroid, according to the Haifa, Israel-based firm. Physicians can also now leverage the beam steering in the phased-array transducer to maximize the energy in the focal point, InSightec said.
Other new safety features aid the physician in identifying anatomical details such as bowels, bones, and nerves, according to the company.
By AuntMinnie.com staff writers
March 5, 2007
Related Reading
FDA clears InSightec's ExAblate 2000 for GE 3T MRI, March 1, 2007
InSightec raises $15 million, August 10, 2006
InSightec to bring Exablate to Australia, Taiwan, June 21, 2006
InSightec reports first North American MRgFUS patient, May 31, 2006
Image guidance evolves into imaging therapy, May 12, 2006
Copyright © 2007 AuntMinnie.com
